Vendor comparison · 2026
Cagrilintide vendors: 21 compared on COAs and price
MetabolicAlso known as AM833
Evidence tier
Regulator-reviewed human evidence
3 human trials · 1 review
- Vendors carrying it
- 21
- 17 with a listed price
- Vendors with checkable COAs
- 8
- 10 publish any certificate
- Lots tested
- 16
- 13 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 14 Sept 2026
- oldest 1 May 2025
- Laboratories named
- 4
- most often ILS Laboratories
- Median label gap
- 2.5%
- 75% of lots within 5% of label
- Median purity
- 99.77%
- 15 of 16 lots at 99% or above
- Lowest price per mg
- $5.95
- peer median $9.90
- Publications located
- 93
- researched since 2021
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Next Gen Peptides has the most checkable Cagrilintide testing in this index: 6 lots assayed by ILS Laboratories, the newest on 17 Aug 2026. The lowest listed price is $5.95 per mg at Ascend Science, against a peer median of $9.90. 21 vendors carrying Cagrilintide are compared below. 8 publish at least one certificate naming a checkable laboratory, 16 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Cagrilintide
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Next Gen PeptidesISO/IEC 17025 | 93.597% | $6.50 (66%) | 6 / 6 | ILS Laboratories | 99.2% | 3.1% | ||
| 2 | Ascend ScienceISO/IEC 17025 | 93.494% | $5.95 (60%) | 0 | — | — | — | — | |
| 3 | Amino ClubISO/IEC 17025Age-gated COAs | 91.498% | $7.00 (71%) | 0 | — | — | — | — | |
| 4 | PeptidePlugs | 91.394% | $6.00 (61%) | 1 / 1 | Freedom Diagnostics Testing | 99.6% | 2.2% | ||
| 5 | One Aminos | 88.789% | $6.50 (66%) | 1 / 1 | United Laboratories | 99.5% | 1.6% | ||
| 6 | Hydro Research PeptidesISO/IEC 17025 | 83.989% | — | 1 / 2 | ILS Laboratories | 99.8% | 14.2% | ||
| 7 | Modern AminosISO/IEC 17025COAs need an account | 80.997% | $9.90 (100%) | 0 | — | — | — | — | no reportVisit site |
| 8 | Northline LabsISO/IEC 17025 | 79.395% | $11.00 (111%) | 0 | — | — | — | — | no reportVisit site |
| 9 | Simple Peptide | 79.192% | — | 0 / 1 | Not named | 99.7% | 0.3% | ||
| 10 | Ascension Peptides | 78.989% | — | 1 / 1 | MZ Biolabs | 100.0% | 1.5% | ||
| 11 | CuroISO/IEC 17025 | 78.897% | $12.40 (125%) | 0 | — | — | — | — | no reportVisit site |
| 12 | Evo Labs Research | 76.187% | $8.00 (81%) | 0 | — | — | — | — | no reportVisit site |
| 13 | Bench Grade Peptides | 74.489% | $13.00 (131%) | 1 / 1 | Freedom Diagnostics Testing | 99.7% | 12.2% | ||
| 14 | Good Science Bio | 69.371% | $9.00 (91%) | 0 | — | — | — | — | no reportVisit site |
| 15 | NeuroLabs Research | 69.391% | $15.59 (158%) | 1 / 1 | Freedom Diagnostics Testing | 99.9% | 6.6% | ||
| 16 | Licensed Peptides | 68.887% | $12.30 (124%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Protide HealthAge-gated COAs | 66.892% | $15.50 (157%) | 0 | — | — | — | — | no reportVisit site |
| 18 | Disguised Alpha | 64.366% | $9.00 (91%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Mile High Compounds | 56.391% | $12.00 (121%) | 0 / 1 | Not named | 99.0% | 2.0% | ||
| 20 | Vertex Labs | 56.172% | — | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 4.8% | ||
| 21 | BioLongevity Labs | 54.572% | $17.00 (172%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Cagrilintide is on file. All 16 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
15 of 16 lots at 99% or above; median 99.77%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 1 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 2 |
| ≥99.5% | 13 |
75% of lots within 5% of the labelled mass; median gap 2.5%.
| Range | lots |
|---|---|
| ≤2% | 5 |
| 2–5% | 7 |
| 5–10% | 2 |
| 10–20% | 1 |
| >20% | 1 |
17 vendors, $5.95 to $17.00; median $9.90.
| Range | vendors |
|---|---|
| $5.00–$10.00 | 9 |
| $10.00–$15.00 | 5 |
| $15.00–$20.00 | 3 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| ILS LaboratoriesUS | 7 | 2 | 44% | Public lookup |
| Freedom Diagnostics TestingUS | 4 | 4 | 25% | Public lookup |
| MZ BiolabsUS | 1 | 1 | 6% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 6% | Public lookup |
3 further records nameno checkable laboratory (a placeholder, a signature line or the vendor’s own name). They are listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2021 — 5 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
93 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.5% across 16 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.91 pts purity across lots, mean label deviation 4.9%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
21 of 21 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
14 of 16 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Cagrilintide?
A long-acting analogue of the hormone amylin, studied for effects on appetite and body weight, frequently in combination with GLP-1 receptor agonists.
Studied in published research for appetite regulation, weight loss and obesity.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in human phase 1 and phase 2 trials, including combinations with semaglutide. PepIndex does not evaluate clinical significance and does not describe administration.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Lancet (London, England) (2021)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2021).
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial — Lancet (London, England) (2023)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2023).
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity — Cardiology in review (2024)
Peer-reviewed article indexed in PubMed, published in Cardiology in review (2024).
- Development of Cagrilintide, a Long-Acting Amylin Analogue — Journal of medicinal chemistry (2021)
Peer-reviewed article indexed in PubMed, published in Journal of medicinal chemistry (2021).
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis — Indian journal of endocrinology and metabolism (2024)
Peer-reviewed article indexed in PubMed, published in Indian journal of endocrinology and metabolism (2024).
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 — EBioMedicine (2025)
Peer-reviewed article indexed in PubMed, published in EBioMedicine (2025).
Indexed studies4 human-evidence of 4
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis — Meta-analysis, 2024
To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes. Systematic review and network meta-analysis. PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase from database inception to 19 August 2023. Eligible randomised controlled trials enrolled adults with type 2 diabetes who received GLP-1RA treatments and…
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — Human — controlled trial, 2025
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown. In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-ma…
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — Human — controlled trial, 2025
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated h…
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Human — controlled trial, 2021
Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management. We assessed the dose-response relationship of cagrilintide regarding the effects on bodyweight, safety, and tolerability. We conducted a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial at 57 sites including hospitals, specialist clinics, and primary care centres in ten …
Evidence digest
What the research on Cagrilintide actually shows
The indexed literature on Cagrilintide includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Cagrilintide is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.